Mestinon Retard

Pyridostigmine bromide, the active ingredient in Mestinon Retard, is a cholinesterase inhibitor presented as an extended‑release tablet for oral use. It treats myasthenia gravis by improving neuromuscular transmission in affected patients and is classified within the anticholinesterase therapeutic class.

GNH USA supplies Mestinon Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for clinical and institutional needs across Europe, Asia and the Americas.

Mestinon Retard, a cholinesterase inhibitor, is indicated for conditions involving impaired neuromuscular transmission.

- Generalized myasthenia gravis: improves overall muscle strength and reduces fatigue. - Ocular myasthenia gravis: alleviates eye‑muscle weakness and diplopia. - Myasthenic crisis prevention: helps maintain adequate neuromuscular function during periods of increased stress or infection.

Adverse reactions may occur with pyridostigmine bromide therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: increased bowel movements. - Abdominal cramps: discomfort in the stomach area. - Excessive salivation: drooling or increased oral secretions. - Muscle cramps: involuntary tightening of muscles. - Increased urinary frequency: more frequent urination.

Serious or Rare Side Effects: - Cholinergic crisis: severe muscle weakness, respiratory failure. - Bradycardia: markedly slow heart rate. - Bronchospasm: narrowing of airways causing breathing difficulty. - Allergic reactions: rash, itching, or anaphylaxis. - Seizures: rare neurologic events.

Before initiating therapy, consider the following safety measures.

- Renal impairment: adjust dose based on renal function. - Asthma or COPD: monitor for bronchospasm. - Concomitant anticholinergics: avoid antagonistic effects. - Sudden discontinuation: taper to prevent cholinergic rebound. - Pregnancy and lactation: safety unknown; use only if benefit outweighs risk. - Store at ambient temperature (below 25 °C): keep in the original pack, protect from moisture.

Pyridostigmine bromide can interact with several medicines.

Major Interactions (Avoid): - Anticholinergic drugs: may reduce therapeutic effect. - Beta‑blockers: can exacerbate bradycardia. - Magnesium‑containing antacids: diminish absorption.

Moderate Interactions (Monitor Closely): - Other cholinesterase inhibitors: risk of cumulative cholinergic toxicity. - Neuromuscular blocking agents: may potentiate muscle weakness. - Diuretics: monitor electrolyte balance.